-- Joy Liu, Executive Vice President and Chief Legal Officer, on May 01, 2026, sold 1,104 shares in Vertex Pharmaceuticals (VRTX) for $469,222. Following the Form 4 filing with the SEC, Liu has control over a total of 20,729 common shares of the company, with 20,729 shares held directly.
SEC Filing:
https://www.sec.gov/Archives/edgar/data/875320/000087532026000183/xslF345X05/wk-form4_1778015480.xml
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EXPD delivered strong Q1 results, with EPS of $1.71 versus $1.47 prior year, significantly beating our $1.37 estimate and $1.33 consensus forecast. Revenue rose 4% to $2.7B from $2.67B, exceeding our $2.59B forecast as Airfreight and Customs strength offset Ocean weakness. Mixed segment performance reflected market bifurcation, with Airfreight revenue surging 14% to $1.03B on favorable pricing while Ocean revenue plummeted 23% to $599M due to capacity oversupply pressuring both pricing and volumes. Management expects global capacity oversupply to persist near-term despite maintaining Ocean profitability. Customs/Other revenue jumped 17% to $1.15B, with double-digit growth across all products, due to hyperscaler and high-value technology customer demand plus tariff complexity. Operating margins reached the company's 30% target despite Middle East disruptions, with productivity gains from 2025 AI and technology investments beginning to materialize.
New Zealand's seasonally-adjusted unemployment rate fell to 5.3% in the March quarter from 5.4% in the December 2025 quarter, data from Stats NZ showed on Wednesday.The seasonally-adjusted number of unemployed people for the quarter was 163,000, down from 165,000 for the December 2025 quarter.The underutilization rate was unchanged at nearly 13% in the quarter, while the participation rate slid 70.4% from 70.5% in the December 2025 quarter.The seasonally-adjusted employment rate was flat at about 67%.The seasonally adjusted youth not in employment, education, or training (NEET) rate rose to over 14% in the March quarter, up from over 13% in the December 2025 quarter."Women aged 20 to 24 continue to have the highest NEET rate, rising 1.9 percentage points to 20.3% in the March quarter," labor market spokesperson Abby Johnston said.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:EMR delivered operating EPS growth of 4% Y/Y to $1.54, though underlying sales growth moderated to 0.5%, impacted by the U.S.-Iran conflict according to management. The beat was supported by share buyback activity. We see 5% underlying orders growth signaling a future recovery, with bookings centered in the high-margin Software & Systems business. Management expects Software segment profitability to enter modest recovery in 2H FY 26. The Software & Systems platform delivered 4% reported growth, with Test & Measurement achieving 16% reported growth, reflecting sustained demand in EMR's growth verticals including semiconductor and aerospace markets. Geographic performance revealed mixed fortunes, with Americas leading growth at 5% Y/Y, while Europe declined 4% and Asia/MEA fell 5%, reflecting broader geopolitical tensions. Adjusted segment EBITA margin compressed 40 bps Y/Y to 27.6% despite favorable mix shift toward higher-margin Software & Systems, with Software margins declining 250 bps to 29.2%.